Compare CARG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | VRDN |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2017 | 2014 |
| Metric | CARG | VRDN |
|---|---|---|
| Price | $34.23 | $22.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $38.32 | $35.46 |
| AVG Volume (30 Days) | 828.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $316,861,000.00 | $5,706,000.00 |
| Revenue This Year | $13.89 | $13.73 |
| Revenue Next Year | $8.91 | $279.00 |
| P/E Ratio | $39.80 | ★ N/A |
| Revenue Growth | ★ 59.92 | N/A |
| 52 Week Low | $26.39 | $13.18 |
| 52 Week High | $41.22 | $34.29 |
| Indicator | CARG | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 54.81 |
| Support Level | $32.67 | $21.62 |
| Resistance Level | $36.46 | $24.86 |
| Average True Range (ATR) | 1.10 | 0.80 |
| MACD | -0.39 | -0.28 |
| Stochastic Oscillator | 8.38 | 37.65 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. It provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.